Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: Comment on the article by Terrier et al

Arthritis and Rheumatism

Volumn 62, Issue 3, 2010, Pages 908-909

  De Vita, Salvatore ^a   Quartuccio, Luca ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RITUXIMAB;

CRYOGLOBULINEMIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LONG TERM CARE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; SYNDROME;

EID: 77649091223     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27310     Document Type: Letter

References (4)

1. Terrier B, Saadoun D, Sene D, Sellam J, Perard L, Coppere B, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009;60:2531-40.
2. De Vita S, Quartuccio L, Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune process, or both? Autoimmun Rev 2008;8:95-9.
3. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20:23-8.
4. Quartuccio L, De Marchi G, Fabris M, De Vita S. Development of type II mixed cryoglobulinemic syndrome after effective and persistent hepatitis C virus eradication. Rheumatology (Oxford) 2007; 4:367-8.